Kankam M - Search Results

1

Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity.

Friedrichsen MH, Endahl L, Kreiner FF, Goldwater R, Kankam M, Toubro S, Nygård SB. Friedrichsen MH, et al. Among authors: kankam m. Mol Metab. 2023 Dec;78:101801. doi: 10.1016/j.molmet.2023.101801. Epub 2023 Sep 9. Mol Metab. 2023. PMID: 37690519 Free PMC article. Clinical Trial.

2

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.

Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, Lau DCW. Enebo LB, et al. Among authors: kankam m. Lancet. 2021 May 8;397(10286):1736-1748. doi: 10.1016/S0140-6736(21)00845-X. Epub 2021 Apr 22. Lancet. 2021. PMID: 33894838 Clinical Trial.

3

Pharmacokinetics and Safety of Vibegron 75 mg Administered as an Intact or Crushed Tablet in Healthy Adults.

King J, Walker A, Aikin D, Haag-Molkenteller C, Kankam M. King J, et al. Among authors: kankam m. Clin Pharmacol Drug Dev. 2022 Nov;11(11):1349-1355. doi: 10.1002/cpdd.1169. Epub 2022 Sep 14. Clin Pharmacol Drug Dev. 2022. PMID: 36104302 Clinical Trial.

4

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers.

Kankam MK, Burns JM, Collett MS, Corrado ML, Hincks JR. Kankam MK, et al. Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0102921. doi: 10.1128/AAC.01029-21. Epub 2021 Aug 9. Antimicrob Agents Chemother. 2021. PMID: 34370575 Free PMC article. Clinical Trial.

5

A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects.

Garey KW, Begum K, Lancaster C, Gonzales-Luna A, Bui D, Mercier J, Seng Yue C, Ducharme MP, Hu M, Vince B, Silverman MH, Alam MJ, Kankam M. Garey KW, et al. Among authors: kankam m. J Antimicrob Chemother. 2020 Dec 1;75(12):3635-3643. doi: 10.1093/jac/dkaa364. J Antimicrob Chemother. 2020. PMID: 32892222 Free PMC article. Clinical Trial.

6

Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y₁₂ Receptor Antagonist Selatogrel in Healthy Subjects.

Zenklusen I, Hsin CH, Schilling U, Kankam M, Krause A, Ufer M, Dingemanse J. Zenklusen I, et al. Among authors: kankam m. Clin Pharmacokinet. 2022 May;61(5):687-695. doi: 10.1007/s40262-021-01097-9. Epub 2021 Dec 28. Clin Pharmacokinet. 2022. PMID: 34961905 Clinical Trial.

7

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects.

Sidharta PN, Melchior M, Kankam MK, Dingemanse J. Sidharta PN, et al. Among authors: kankam mk. Drug Des Devel Ther. 2019 Mar 22;13:949-964. doi: 10.2147/DDDT.S199051. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 30962677 Free PMC article. Clinical Trial.

8

AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study.

Gillies H, Niven R, Dake BT, Chakinala MM, Feldman JP, Hill NS, Hoeper MM, Humbert M, McLaughlin VV, Kankam M. Gillies H, et al. Among authors: kankam m. ERJ Open Res. 2023 Mar 13;9(2):00433-2022. doi: 10.1183/23120541.00433-2022. eCollection 2023 Mar. ERJ Open Res. 2023. PMID: 36923571 Free PMC article.

9

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout.

Kankam M, Hall J, Gillen M, Yang X, Shen Z, Lee C, Liu S, Miner JN, Walker S, Clauson V, Wilson D, Nguyen M. Kankam M, et al. J Clin Pharmacol. 2018 Sep;58(9):1214-1222. doi: 10.1002/jcph.1119. Epub 2018 May 7. J Clin Pharmacol. 2018. PMID: 29733447 Free PMC article. Clinical Trial.

10

Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study.

Alvarado D, Maurer M, Gedrich R, Seibel SB, Murphy MB, Crew L, Goldstein J, Crocker A, Vitale LA, Morani PA, Thomas LJ, Hawthorne TR, Keler T, Young D, Crowley E, Kankam M, Heath-Chiozzi M. Alvarado D, et al. Among authors: kankam m. Allergy. 2022 Aug;77(8):2393-2403. doi: 10.1111/all.15262. Epub 2022 Mar 3. Allergy. 2022. PMID: 35184297 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

31 results

Search Page